Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012

Background: Whether aromatase inhibitors (AIs) increase the risk of cardiovascular (CV) events, compared to tamoxifen, in women with breast cancer is still debated. We evaluated the association between AI and CV outcomes in a large population-based cohort of breast cancer women. Methods: By using healthcare utilization databases of Lombardy (Italy), we identified women ≥50 years, with new diagnosis of breast cancer between 2009 and 2015, who started adjuvant therapy with either AI or tamoxifen. We estimated the association between exposure to AI and CV outcomes (including myocardial infarction, ischemic stroke, heart failure or any CV event) by a Cox proportional hazard model with inverse probability of treatment and censoring weighting. Results: The study cohort included 26,009 women starting treatment with AI and 7937 with tamoxifen. Over a median follow-up of 5.8 years, a positive association was found between AI and heart failure (Hazard Ratio = 1.20, 95% CI: 1.02 to 1.42) and any CV event (1.14, 1.00 to 1.29). The CV risk increased in women with previous CV risk factors, including hypertension, diabetes and dyslipidemia. Conclusions: Adjuvant therapy with AI in breast cancer women aged more than 50 years is associated with increased risk of heart failure and combined CV events.

Download Full-text

Thoracic aortic aneurysm and dissection: Increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002

Journal of Vascular Surgery ◽

10.1016/j.jvs.2007.07.017 ◽

2007 ◽

Vol 46 (3) ◽

pp. 609 ◽

Cited By ~ 3

Author(s):

C. Olsson ◽

S. Thelin ◽

E. Stahle

Keyword(s):

Aortic Aneurysm ◽

Thoracic Aortic Aneurysm ◽

Population Based ◽

Population Based Study ◽

Improved Outcomes ◽

Aortic Aneurysm And Dissection

Download Full-text

Abstract P2-18-01: Single modality adjuvant therapy with radiation (RT) alone or endocrine therapy (ET) alone in women ≥65 years with early stage, hormone receptor positive breast cancer treated with breast-conserving surgery: A population-based analysis

10.1158/1538-7445.sabcs19-p2-18-01 ◽

2020 ◽

Author(s):

Mira Goldberg ◽

Rinku Sutradhar ◽

Lawrence Paszat ◽

Timothy Whelan ◽

Sumei Gu ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Early Stage ◽

Breast Conserving Surgery ◽

Population Based ◽

Hormone Receptor Positive ◽

Single Modality ◽

Positive Breast Cancer

Download Full-text

Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2011.35.0058 ◽

2011 ◽

Vol 29 (24) ◽

pp. 3255-3262 ◽

Cited By ~ 38

Author(s):

Thomas A. Abrams ◽

Rick Brightly ◽

Jianbin Mao ◽

Gregory Kirkner ◽

Jeffrey A. Meyerhardt ◽

...

Keyword(s):

Colon Cancer ◽

Adjuvant Chemotherapy ◽

Adjuvant Therapy ◽

Performance Status ◽

Population Based ◽

Stage Ii ◽

Patient Demographics ◽

Cancer Care Facilities ◽

Provider Characteristics ◽

Resected Stage

Purpose Previous studies have examined predictors for initiation of adjuvant chemotherapy in stages II and III colon cancer. However, little is known regarding the use of specific chemotherapy regimens or treatment duration. Patients and Methods We studied treatment records for 2,560 patients with stage II or III colon cancer who received adjuvant chemotherapy between January 2004 and April 2010 at US cancer care facilities participating in a nationwide, commercially available chemotherapy order entry system that captures patient demographics, stage, and details of chemotherapy treatment. Multivariate analyses of prospectively recorded patient and provider characteristics identified predictors of specific therapeutic approaches. Results The addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy increased during the study period (P trend < .001), and this combination represented 78% and 90% of adjuvant chemotherapy in stage II or III disease, respectively, by 2007. Older patients, those with diminished performance status, and those treated in a private practice setting were significantly less likely to receive oxaliplatin. Thirty percent of patients discontinued adjuvant therapy after less than 3 months. Older age, oxaliplatin-containing therapy, and receipt of treatment from a physician with a low volume of patients were each independently associated with premature discontinuation. Six percent of patients received bevacizumab as part of their adjuvant regimen. Conclusion After 2004, oxaliplatin and fluoropyrimidine-based therapy rapidly became the predominant adjuvant treatment for both stage II and stage III colon cancer in this large US cohort. Both increasing patient age and lower volume of an oncologist's practice were associated with early termination of adjuvant therapy.

Download Full-text